The company is a leading international enterprise in modern traditional Chinese medicine, and is committed to developing into a leading integrated pharmaceutical and health service solution provider with global influence in China. We are “people-oriented, precise and innovative”, continuously promote the progress of medicine and health care, so that everyone can enjoy the beauty and hope of life. The company's main business is the production and sale of pharmaceuticals. Main products: Compound Danshen Dropping Pills, Serum Nourishing Brain Pellets, Astragalus Ginseng Yiqi Droplets, Temozolomide Capsules (Diqing), Silybin Capsules (Shuilinjia), and Yiqi Fumei for Injection. Corporate honors: “China's Top 100 Pharmaceutical Manufacturing Companies in China”, “2023 China's Top 10 Traditional Chinese Medicine R&D Strength”, “2023 China's Top 50 Pharmaceutical Innovation Enterprises”, “2023 China's Top 100 Pharmaceutical Innovation Enterprises”, “2023 Top 50 Chinese Pharmaceutical Enterprises Comprehensive Competitiveness Index”, “2022 2023 Pharmaceutical Industry Independent Innovation Pioneer Enterprise”, “Top 20 Most Influential and Important Enterprises in International Influence”, “2023 Best Practice Case for Traditional Chinese Medicine Inheritance and Innovation”, “2023 Listed Companies” “ESG Best Practice Case”, “Excellent Brand Enterprise of Chinese Ethnic Medicine in the 2023-2023 Year”, and “First Prize for Digital Quality Management in the Whole Industry Chain of Modern Traditional Chinese Medicine Enterprises”.
相关临床试验
29
4 进行中
药物批准
18
批准总数
监管机构
1
监管机构数
成立时间
1998
进行中（未招募）
1
3.5%
已完成
4
13.8%
尚未招募
3
10.3%
招募中
2
6.9%
Unknown
19
65.5%
- The FDA accepted the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) through Tasly's Device Master File on January 9, 2026. - The "Tasly 3P Characterization of MSCs Assay" evaluates three core attributes: Property (cell identity), Purity (freedom from contaminants), and Potency (functional activity). - This regulatory milestone addresses historical issues with variable clinical outcomes and safety risks including tumor formation in MSC therapies. - The new standard aligns with modern scientific understanding that MSCs function primarily through paracrine signaling rather than differentiation capabilities.
- Mauna Kea Technologies obtained NMPA approval for its Cellvizio Gen 3 confocal laser endomicroscopy platform in China following a three-year certification process. - The five-year registration authorizes use of the advanced imaging system with the company's full range of confocal probes for real-time cellular visualization during endoscopic procedures. - The approval reopens the Chinese market for Mauna Kea independently of its joint venture with Tasly, positioning the company to capitalize on strong demand for precision diagnostic technologies in interventional endoscopy.
- French biotech Pharnext's lead drug PXT3003 for Charcot-Marie-Tooth disease type 1A failed to demonstrate superiority over placebo in Phase 3 PREMIER trial due to unexpected placebo response. - Despite the setback, Pharnext remains optimistic, citing 10 years of accumulated data and an ongoing Phase 3 trial with Chinese partner Tasly that could support regulatory submission. - PXT3003, a combination of baclofen, naltrexone, and sorbitol, maintained its favorable safety profile and showed no disease deterioration in treated patients during the study period.
